NCI Chooses Veterinary Biopharma as Select Manufacturing Contractor

September 20, 2019

By The Life Science Report

Source: Streetwise Reports   09/18/2019

The contract’s meaning, terms and benefits and the California firm’s near-term catalysts are discussed in an H.C. Wainwright & Co. report.

In a Sept. 12 research note, H.C. Wainwright & Co. analyst Swayampakula Ramakanth reported that Kindred Biosciences Inc. (KIN:NASDAQ) was chosen by the National Cancer Institute (NCI) as one of three Current Good Manufacturing Practice (cGMP) contractors for the PREVENT Cancer Preclinical Drug Development Program.

This means that as a select contractor for this NCI-supported program, Kindred, which modifies human therapies for cats, dogs and horses, may “provide manufacturing, formulation and analytical services needed for the preclinical development of innovative cancer prevention interventions and biomarkers” developed through PREVENT, explained Ramakanth. The maximum contract amount is $49.95 million; the term is four years. Also as a manufacturing pool member, Kindred may bid for future contracts.


Get our Weekly Commitment of Traders Report: - See where the biggest traders (Hedge Funds and Commercial Hedgers) are positioned in the futures markets on a weekly basis.




Get Our Free Metatrader 4 Indicators - Put Our Free MetaTrader 4 Custom Indicators on your charts when you join our Weekly Newsletter






Ramakanth highlighted that the benefits of this new development are twofold. One, having been chosen by “a leading institution for the development of novel therapies against cancer” validates Kindred’s expertise in cGMP manufacturing and project management of biologicals, which it executes on at its Burlingame, Calif., operation. Two, the biopharma could receive nondilutive cash flow from the contract.

Looking to H2/19 for its pipeline therapies, noted Ramakanth, Kindred intends to meet with the European Medicines Agency to discuss the regulatory path for Mirataz (mirtazapine transdermal ointment) in the European Union. It expects a decision in Q4/19 from the U.S. Food and Drug Administration on intravenous Zimeta (dipyrone).

Also, in H2/19, the biopharma expects to announce the results from the pilot effectiveness studies of two clinical molecules: the anti-L-4/IL-13 SINK molecule for atopic dermatitis in dogs and the anti-TNF antibody for inflammatory bowel disease in dogs.

H.C. Wainwright has a Buy rating and a $17.99 per share target price on Kindred Biosciences, whose stock is currently trading at around $7.09 per share.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.

Disclosures from H.C. Wainwright & Co., Kindred Biosciences Inc., First Take, September 12, 2019

Investment Banking Services include, but are not limited to, acting as a manager/co-manager in the underwriting or placement of securities, acting as financial advisor, and/or providing corporate finance or capital markets-related services to a company or one of its affiliates or subsidiaries within the past 12 months.

I, Swayampakula Ramakanth, Ph.D., Sean Lee, Sean Kang and Arthur He, Ph.D., certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies.

None of the research analysts or the research analyst’s household has a financial interest in the securities of Kindred
Biosciences, Inc. (including, without limitation, any option, right, warrant, future, long or short position).

As of August 31, 2019 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of Kindred Biosciences, Inc.

Neither the research analyst nor the Firm has any material conflict of interest in of which the research analyst knows or has reason to know at the time of publication of this research report.

The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services.

The firm or its affiliates received compensation from Kindred Biosciences, Inc. for non-investment banking services in
the previous 12 months.

The Firm or its affiliates did receive compensation from Kindred Biosciences, Inc. for investment banking services within
twelve months before, and will seek compensation from the companies mentioned in this report for investment banking
services within three months following publication of the research report.

The Firm does not make a market in Kindred Biosciences, Inc. as of the date of this research report.

( Companies Mentioned: KIN:NASDAQ,
)